Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer

The opinion regarding sexual and vaginal function of patients with advanced cervical cancer treated primarily by chemoradiotherapy has still not been formed, mainly due to inappropriate methodology as the control group was comprised of healthy women. The aim of this study is to, by means of intervie...

Full description

Bibliographic Details
Main Authors: Dženita Ljuca, Goran Marošević
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2011-02-01
Series:Bosnian Journal of Basic Medical Sciences
Subjects:
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/2628
id doaj-a5d7a0a96a92419c8c0d5c7a0932ea9a
record_format Article
spelling doaj-a5d7a0a96a92419c8c0d5c7a0932ea9a2020-11-25T00:28:50ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBosnian Journal of Basic Medical Sciences1512-86011840-48122011-02-0111110.17305/bjbms.2011.2628374Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancerDženita Ljuca0Goran Marošević1University Clinical Centre Tuzla, Department of Gynaecology and Obstetrics2University Clinical Centre Tuzla, Department of Oncology and RadiotherapyThe opinion regarding sexual and vaginal function of patients with advanced cervical cancer treated primarily by chemoradiotherapy has still not been formed, mainly due to inappropriate methodology as the control group was comprised of healthy women. The aim of this study is to, by means of interview, evaluate vaginal and sexual function of patients with advanced cervical cancer before and after chemoradiotherapy and compare the results. A number of 35 patients were irradiated by teleradiotherapy dose of 45 Gy in 25 fractions over 5 weeks to the pelvis and additional 20-24 Gy in 4-6 fractions were given by intracavitary HDR brachytherapy. Patients received 40 mg/m2 of cisplatin once a week, which is a total of 4-6 cycles of cisplatin. Patients answered the questions in a form of a questionnaire specifically created for cervical cancer (EORTC-QLQ-Cx 24), for the period immediately before diagnosed cervical cancer (thus being a control group). They also answered the same questions for the period starting 12 months after the completion of concomitant chemoradiotherapy, and were an experimental group at the time. For the testing of statistical significance of differences among the examined groups parameter and non-parameter tests were used (the Wilcoxon signed ranks test and Student’s t-test). The difference p<0.05 was considered statistically significant. Vaginal problems of patients after chemoradiotherapy were statistically reduced (44 versus 0; p<0.0001). There is no statistical significance in the vaginal function among the analyzed groups but weaker pain during intercourse was registered after chemoradiotherapy (p=0.009). After chemoradiotherapy, patients’ vaginal function is extremely improved whereas there is no difference in the sexual function. Pain during intercourse is statistically reduced after chemoradiotherapy.https://www.bjbms.org/ojs/index.php/bjbms/article/view/2628sexual functionvaginal functionchemoradiotherapycervical cancer
collection DOAJ
language English
format Article
sources DOAJ
author Dženita Ljuca
Goran Marošević
spellingShingle Dženita Ljuca
Goran Marošević
Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
Bosnian Journal of Basic Medical Sciences
sexual function
vaginal function
chemoradiotherapy
cervical cancer
author_facet Dženita Ljuca
Goran Marošević
author_sort Dženita Ljuca
title Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
title_short Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
title_full Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
title_fullStr Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
title_full_unstemmed Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer
title_sort impact of chemoradiotherapy on vaginal and sexual function of patients with figo iib cervical cancer
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
series Bosnian Journal of Basic Medical Sciences
issn 1512-8601
1840-4812
publishDate 2011-02-01
description The opinion regarding sexual and vaginal function of patients with advanced cervical cancer treated primarily by chemoradiotherapy has still not been formed, mainly due to inappropriate methodology as the control group was comprised of healthy women. The aim of this study is to, by means of interview, evaluate vaginal and sexual function of patients with advanced cervical cancer before and after chemoradiotherapy and compare the results. A number of 35 patients were irradiated by teleradiotherapy dose of 45 Gy in 25 fractions over 5 weeks to the pelvis and additional 20-24 Gy in 4-6 fractions were given by intracavitary HDR brachytherapy. Patients received 40 mg/m2 of cisplatin once a week, which is a total of 4-6 cycles of cisplatin. Patients answered the questions in a form of a questionnaire specifically created for cervical cancer (EORTC-QLQ-Cx 24), for the period immediately before diagnosed cervical cancer (thus being a control group). They also answered the same questions for the period starting 12 months after the completion of concomitant chemoradiotherapy, and were an experimental group at the time. For the testing of statistical significance of differences among the examined groups parameter and non-parameter tests were used (the Wilcoxon signed ranks test and Student’s t-test). The difference p<0.05 was considered statistically significant. Vaginal problems of patients after chemoradiotherapy were statistically reduced (44 versus 0; p<0.0001). There is no statistical significance in the vaginal function among the analyzed groups but weaker pain during intercourse was registered after chemoradiotherapy (p=0.009). After chemoradiotherapy, patients’ vaginal function is extremely improved whereas there is no difference in the sexual function. Pain during intercourse is statistically reduced after chemoradiotherapy.
topic sexual function
vaginal function
chemoradiotherapy
cervical cancer
url https://www.bjbms.org/ojs/index.php/bjbms/article/view/2628
work_keys_str_mv AT dzenitaljuca impactofchemoradiotherapyonvaginalandsexualfunctionofpatientswithfigoiibcervicalcancer
AT goranmarosevic impactofchemoradiotherapyonvaginalandsexualfunctionofpatientswithfigoiibcervicalcancer
_version_ 1725334075529494528